CONSULTANT HAEMATOLOGIST
Associate Professor Michael Low
MBBS BMedSci FRACP FRCPA
A/Prof Michael Low is a Haematologist at Monash Medical Centre, as well as St John of God Berwick where he serves on the medical advisory committee. He undertook his undergraduate training at the University of Melbourne for which he was awarded an MBBS/BMedSci. A/Prof Low then undertook his specialty training through the Royal Melbourne Hospital, Alfred Hospital and Monash Medical Centre. He is a fellow of both the Royal Australasian College of Physicians (RACP) as well as the Royal College of Pathologists Australasia (RCPA)
Dr Low undertook his PhD studies jointly at Monash University as well as the Walter and Eliza Hall Research Institute for which he was awarded the prestigious Gus Nossal Award by the National Health and Medical Research Council of Australia for his studies into survival pathways in myeloma. Dr Low is the Myeloma lead at Monash Health and is the principal investigator on a number of clinical trials in myeloma at Monash Medical Centre.
Practice Interests
A/Prof. Low’s clinical and research interests include myeloma, MGUS and other haematological malignancies (eg. lymphoma). Dr Low has published in numerous international journals including Blood, Nature communications, Lancet Haematology, Journal of Nutrition, Canadian Medical Association Journal, British Journal of Haematology and Cochrane Library of Systematic Reviews.
A/Prof Low consults out of St John of God Hospital, Berwick and will see patients with any haematological disorder including haematological malignancies, cytopenias, clots and iron deficiency.
Practice Locations
A/Prof. Michael Low consults privately in rooms located at St John of God Hospital Consulting Suites, Berwick.
TeleHealth appointments are available.
St John of God Hospital Consulting Suites
Ground Floor
75 Kangan Drive
Berwick VIC 3806
Tel: 03 5910 6100
Fax: 03 5910 6101
Hospital Accreditation
Extended Profile
A/Prof Michael Low
– Key Research, Journal & Book Publications, Presentations &/or Awards
Selected Journal Publications (Recent)
- Gong JN, Djajawi TM, Moujalled DM, Pomilio G, Khong T, Zhang LP, Fedele PL, Low MS, Anderson MA, Riffkin CD, White CA, Lan P, Lessene G, Herold MJ, Strasser A, Spencer A, Grigoriadis G, Wei AH, van Delft MF, Roberts AW, Huang DCS. Re-appraisingcassays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins. Cell Death Differ. 2025 Apr 9. doi: 10.1038/s41418-025-01487-7.
- Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10.):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
- Fedele PL, Liao Y, Gong J, Yao Y, van Deflt MF, Low MSY, Tai L, Herold MJ, Jackson JT, Teh C, Tan T, Gray DH, Tellier J, Grigoriadis G, Huang DCS, Shi W, Nutt SL, Willis SN. The transcription factor IRF4 represses pro-apoptotic BMF and BIM to licence Multiple Myeloma survival. Leukemia 2021, 35(7), pp. 2114–2118 doi: 10.1038/s41375-020-01078-0.
Professional Memberships
Fellow of Royal Australasian College of Physicians (FRACP)
Australasian Leukaemia and Lymphoma Group (ALLG)
Member of Haematology society of Australia and New Zealand (HSANZ)
